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A B S T R A C T
Successful chemotherapy with paclitaxel (PTX) is impeded by multidrug resistance (MDR)
in tumor cells. In this study, lipid-albumin nanoassemblies co-loaded with borneol and
paclitaxel (BOR/PTX LANs) were prepared to circumvent MDR in C6 glioma cells. The
physiochemical properties including particle size, encapsulation efficiency and morphol-
ogy were evaluated in vitro. Quantitative and qualitative investigations of cellular uptake
were carried out in C6 glioma cells. The cytotoxicity of the BOR/PTX LANs was determined
by MTT assay. After that, the tumor targeting was also evaluated in C6 glioma bearing mice
by in vivo imaging analysis. BOR/PTX LANs have a higher entrapment efficiency (90.4 ± 1.2%),
small particle size (107.5 ± 3.2 nm), narrow distribution (P.I. = 0.171 ± 0.02). The cellular uptake
of PTX was significantly increased by BOR/PTX LANs compared with paclitaxel loaded lipid-
albumin nanoassemblies (PTX LANs) in quantitative research.The result was further confirmed
by confocal laser scanning microscopy qualitatively. The cellular uptake was energy-, time-
and concentration-dependent, and clathrin- and endosome/lysosome-associated path-
ways were involved. The BOR/PTX LANs displayed a higher cytotoxicity agaist C6 glioma
cells in comparion with PTX LANs and Taxol. Moreover, the encapsulation of BOR in LANs
obviously increased the accumulation of the drug in tumor tissues, demonstrating the tumor
targeted ability of BOR/PTX LANs. These results indicated that BOR/PTX LANs could over-
come MDR by combination of drug delivery systems and P-gp inhibition, and shown the
potential for treatment of gliomas.
© 2015 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords:
Borneol
Paclitaxel
Lipid-albumin nanoassemblies
C6 glioma cells
P-gp inhibition
* Corresponding author. School of Pharmacy, Shenyang Pharmaceutical University, China.
E-mail address: chenggang63@hotmail.com, chenggangsypha@163.com (G. Cheng).
Peer review under responsibility of Shenyang Pharmaceutical University.
http://dx.doi.org/10.1016/j.ajps.2015.04.004
1818-0876/© 2015 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 6 3 – 3 7 1
Available online at www.sciencedirect.com
journal homepage: www.elsevier.com/ locate /a jps
HOSTED BY
ScienceDirect
1. Introduction
Gliomas are the most common primary brain tumors. It ac-
counts for about 80% of all brain tumors, with an incidence
rate of approximately 7 per 100,000 worldwide. Patients with
gliomas may have several neurological symptoms such as head-
aches, seizures, memory loss, vomiting, visual changes and so
on [1–3]. Gliomas are resistant to many therapy methods, in-
cluding chemotherapy, radiation and other adjuvant therapies.
The failure of chemotherapy in gliomas is often due to the de-
velopment of multidrug resistance (MDR) by tumor cells. Over
the past years, various mechanisms of MDR have been pro-
posed, including the overexpression of MDR pumps like
P-glycoprotein (P-gp) [4], reduced in topoisomerase activity [5],
modifications in glutathione metabolism [6] or altered expres-
sion of apoptosis-associated protein Bcl-2 [7] and tumor
suppressor protein p53 [8]. One of the major cause is due to
the overexpression of membrane-bound proteins such as P-gp.
Many P-gp substrates such as doxorubicin and paclitaxel (PTX)
were expelled out of the tumor cells, resulting in the reduc-
tion of accumulation of drugs in the tumor cells, thereby causing
the treatment failure [9]. On the other hand, treatment with
high doses or combination chemotherapy is insufficient to
inhibit the function of P-gp. In addition, these treatments are
often related to toxic side effects in patients, because most anti-
tumor drugs do not have specificity towards the tumor cells
[10]. Several therapeutic strategies have been explored for over-
coming MDR.
Nano-drug delivery systems, such as liposomes, lipid
nanoparticles, polymeric micelles and microemulsions have
gained much attention to overcome MDR [11]. Firstly, they could
improve the solubility of drugs. Secondly, the nanocarriers could
enter into the glioma cells by endocytosis, which was able to
circumvent MDR of the tumor cells [12]. In addition, the
nanocarriers were expected to act as the intracellular drug res-
ervoirs after entering the tumor cells, which could protect anti-
tumor drugs from degradation and increase the drug efficacy
[13]. However, most of the free drugs were still expelled by the
P-gp in tumor cells [14,15].
P-gp inhibitors have been extensively investigated for in-
hibiting P-gp efflux pump [16]. Different generations of
pharmacological P-gp inhibitors have been studied in last
decades, but most of the drug trials were disappointing as the
inhibitors exhibited high systemic toxicity [17]. Other factors
such as the limited solubility of P-gp inhibitors in aqueous so-
lution have also contributed to the failure of P-gp inhibitors
in overcoming MDR. To date, co-encapsulation of P-gp sub-
strates and P-gp inhibitors in nanocarriers was a promising
alternative for enhancing the anti-tumor drugs uptake in the
tumor cells. Verapamil, a first generation p-gp inhibitor, has
been reported to be able to reverse completely the resistance
caused by P-gp in vitro[18]. It was reported that the intracel-
lular accumulation of PTX was significantly increased, and the
PTX was more effective in inhibiting the growth of the tumor
cells when it was co-encapsulated with verapamil in polymer
micelles [19,20]. In recent studies, the third-generation P-gp
modulator, tariquidar, was co-encapsulated with paclitaxel in
long circulating liposomes. The co-loaded liposomes resulted
in about 100-fold lower IC50 than paclitaxel liposomes. There-
fore, it is effective to overcome MDR of the tumor cells by co-
encapsulation of the P-gp inhibitors and the anti-tumor drugs
using a nano-drug delivery system [21].
Borneol (BOR), a simple bicyclic monoterpene, is widely used
in traditional Chinese medicine, such as the “Xingnaojing” in-
jection. Some studies have demonstrated that borneol is able
to loosen intercellular tight junctions [22] and inhibit the action
of P-gp on the cell membrane [23]. We speculate that co-
encapsulation of BOR and PTX could increase the uptake of
PTX by the brain glioma cells.
In our previous work, we have prepared PTX-loaded lipid-
protein nanoparticles, which exhibited high drug entrapment
efficiency, small particle size and good biocompatibility [24].
In the current research, the BOR and PTX were co-encapsulated
in the lipid-albumin nanoassemblies to achieve higher cellu-
lar uptake and stronger anti-tumor efficacy in C6 glioma cells
by inhibiting P-gp. Additionally, the tumor-targeted efficacy was
also increased in glioma-bearing mice.
2. Materials and methods
2.1. Materials
Paclitaxel (PTX) was obtained from Tianfeng Bioengineering
Technology Co., Ltd. (Liaoning, China). Borneol (BOR) was ob-
tained from Yunnan Linyuan spicery Co., Ltd. (Yunnan, China).
Egg yolk lecithin PL 100M was purchased from the Q.P. Corpo-
ration (Tokyo, Japan), Cremophor EL was kindly gifted by the
BASF Corporation (Ludwigshafen, Germany), 3-(4, 5-Dimethyl-
thiazol-2-yl)-2, 5-diphenyl- tetrazoliumbromide (MTT), Bovine
serum albumin (BSA) and Rhodamine 6G were obtained from
Sigma–Aldrich (St. Louis, MO, USA). Penicillin–streptomycin,
DMEM, fetal bovine serum (FBS) and 0.25% (w/v) trypsin–
0.03% (w/v) EDTA solution were obtained from Gibco BRL
(Gaithersberg, MD, USA). 4, 6- diamidino- 2 -phenylindole (DAPI),
BCA kit and Triton X-100 were purchased from Beyotime Bio-
technology Co., Ltd. (Nantong, China). 4% paraformaldehyde
was obtained from Solarbio Technology Co., Ltd. (Beijing, China).
1, 1′-Dioctadecyl-3, 3, 3′, 3′- tetramethylindotricarbocyanine
Iodide (DIR) was purchased from Biotium (Hayward, CA). All
other chemicals and solvents were of analytical or chromato-
graphic grade.
Taxol injection was prepared according to the clinical for-
mulation. PTX (0.012 g) was dissolved in anhydrous ethanol
(1 ml) and cremophor EL (1 ml) under magnetic stirring. Taxol
injection was diluted with saline before test [25].
The C6 giloma cells were gifted by Prof. Jingyu Yang (De-
partment of Pharmacology, Shenyang Pharmaceutical University,
Shenyang, China). The cells were cultured in DMEM medium,
supplemented with 10% FBS, 100 IU/ml penicillin and 100 μg/
ml streptomycin sulfate. All the cells were grown in incubators
maintained at 37 °C with 5% CO2 under fully humidified con-
ditions. All experiments were performed on cells during the
logarithmic phase of growth.
Male Kunming mice (18–22 g) were obtained from the Ex-
perimental Animal Center (Shenyang Pharmaceutical University,
China). All the animal experiments were approved by Shengyang
Pharmaceutical University Ethics Committee and according to
the Guidelines for the Use of Laboratory Animals.
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2.2. Preparation of BOR/PTX LANs
The BOR/PTX LANs were prepared by a desolvation-
ultrasonication technique as described in our previous work
[24]. In brief, 5 ml of BSA aqueous solution was prepared at a
concentration of 40 mg/ml, BOR (0.01 g), PTX (0.01 g) and PL
100M (0.10 g) were dissolved in 0.3 ml anhydrous ethanol, and
then the ethanol solution were added dropwise to the BSA so-
lution with stirring at room temperature.The resulting mixture
was sonicated by a probe ultrasonication (JY92-Ⅱ, Ningbo, China).
Then, the anhydrous ethanol was removed by rotary evapo-
ration.Then, the samples were centrifuged and passed through
a 0.22 μm filter membrane to obtain BOR/PTX LANs.
The preparation method for borneol and rhodamine 6G co-
loaded LANs (BOR/RDM LANs) was the same as that for BOR/
PTX LANs, except that PTX was replaced with rhodamine 6G.
Rhodamine 6G loaded LANs (RDM LANs) were prepared using
the same procedure, except for without addition of BOR.
The preparation method for borneol and DIR co-loaded LANs
(BOR/DIR LANs) was the same as that for BOR/PTX LANs, except
that PTX was replaced with DIR. DIR loaded LANs (DIR LANs)
were prepared using the same procedure, except for without
addition of BOR.
2.3. Determination of entrapment efficiency
The entrapment efficiency of BOR/PTX LANs was determined
as described in our previous study [24]. The solubility of PTX
in BOR/PTX LANs (>1.6 mg/ml) was far higher than that of free
PTX in water (<1 μg/ml). Therefore, the amount of free PTX in
BOR/PTX LANs could be neglected. In order to determine the
weight of drug in BOR/PTX LANs, acetonitrile was used to pre-
cipitate BSA, and release PTX from the BOR/PTX LANs. After
centrifugation at 12,000 rpm for 10 min, 20 μl of the superna-
tant was injected into an HPLC system.The drug encapsulation
efficiency (EE) was calculated as follows:
EE
W
W
total drug
feeding drug
%( ) = × 100
Where, W total drug represents the weight of drug in BOR/PTX
LANs, W feeding drug represents the weight of feeding drug.
2.4. Characterization of BOR/PTX LANs
The size distribution, polydispersity index (P.I.) of the BOR/
PTX LANs were evaluated by dynamic light scattering (DLS) (PSS
NICOMP 380, USA). The morphology was observed using trans-
mission electron microscopy (TEM) (JEOL, Tokyo, Japan).
2.5. Cellular uptake
2.5.1. Cellular uptake of PTX
Cellular uptake of PTX was determined in the presence or
absence of known various concentrations of BOR ranging from
0.001 to 10.0 μg/ml in C6 glioma cells. Cyclosporine A (CsA) was
used as positive control, and the inhibition concentration was
set at 20.0 μg/ml throughout the studies. C6 cells (2 × 105 per
1 ml/well) were seeded in 24-well plates and incubated for 24 h.
After they reached 80% confluence, Taxol solution (50 μg/ml)
with various concentrations of BOR were incubated for 2 h at
37 °C. After 2 h incubation, the cells were washed with ice-
cold PBS for 3 times, the cells were lysed with 0.3 ml of 1% Triton
X-100. The concentration of PTX in cell lysate was deter-
mined using HPLC method described above. The cell protein
content was determined by the BCA protein assay kit. Cellu-
lar uptake efficiency (%) was calculated as the following
equation.
Cellular uptake efficiency C P C Ps s c c%( ) = ( ) ( ) × 100
Where Cs represents the PTX concentration of sample, Ps rep-
resents the protein content of sample, Cc represents the PTX
concentration of control, and Pc represents the protein content
of control.
2.5.2. The effect of incubation time on cellular uptake
The time-dependent internalization of PTX with or without BOR
(1.0 μg/ml) was evaluated in C6 glioma cells at predeter-
mined time intervals (0.5, 1.0 and 2.0 h), cellular uptake was
conducted as described above.
2.5.3. Cellular uptake of BOR/PTX LANs
Cellular uptake of PTX from Taxol solution, PTX LANs and BOR/
PTX LANs with BOR (or CsA) or without BOR (or CsA) were
evaluated in C6 glioma cells after 2.0 h incubation. The cellu-
lar uptake experiment was conducted as described above.
2.5.4. Confocal microscopy studies
For the qualitative study, C6 glioma cells (2 × 104 per 1 ml/
well) were seeded in 24-well plates and incubated for 24 h. The
cells were washed and incubated with Rhodamine 6G solu-
tion (RDM solution), RDM LANs and BOR/DIR LANs at 37 °C for
2 h. Then the cells were washed with ice-cold PBS for 3 times,
and fixed with 4% paraformaldehyde for 20 min.The nuclei were
counterstained by DAPI. The coverslips were mounted on mi-
croscope slides and the intracellular accumulation was
visualized under confocal laser scanning microscope (Leica,
Germany). The time- and concentration-dependent cellular
uptake were evaluated.
2.5.5. Uptake mechanism
C6 glioma cells (2 × 105 per 1 ml/well) were seeded in 24-well
plates and incubated for 24 h. After checking the confluency
and morphology, various inhibitors of PBS (control), chlor-
promazine (10 μg/ml), sodium azide (3 μg/ml), colchicines (8 μg/
ml), indomethacin (6 μg/ml), quercetin (6 μg/ml), amonium
chloride (10 mM) were added and incubated for 1 h. Then the
medium was withdrawn from the wells and the PTX LANs
(50 μg/ml) and BOR/PTX LANs (50 μg/ml) were added. After 2 h
incubation, the cells were processed and cellular uptake effi-
ciency (%) was calculated as described above. In order to
investigate the effect of temperature on the cellular uptake,
the cells were also incubated under both 37 °C and 4 °C.
2.6. In vitro cytotoxicity
The cell viability was measured using the methylthiazolete-
trazolium (MTT) method. In order to determine the toxicity of
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different formulations, C6 glioma cells were seeded in 96-
well plates at a density of 5.0 × 103 cells/well. After 24 h
incubation, the cells were treated with 200 μl medium con-
taining Taxol solution, PTX LANs and BOR/PTX LANs at serial
concentrations, respectively. After 72 h incubation, a total of
20 μl MTT (5 mg/ml) and 180 μl fresh medium were supplied
to each well followed by incubation for another 4 h, and then
the formazan crystals were dissolved in 200 μl DMSO. The ab-
sorbance at 492 nm of each well was measured in a microplate
reader (Model 500, USA). Cell viability was determined and IC50
values were calculated using nonlinear regression analysis.
2.7. In vivo image
In vivo real-time fluorescence imaging analysis was used to
evaluate the effect of the biodistribution of nanoparticles. The
tumor model was established by injecting subcutaneously of
3 × 107 C6 cells in the right flanks of the mice. After 10 days,
the mice were randomly divided into three groups (n = 3) and
were i.v. administrated via tail vein injection with DIR solu-
tion, DIR LANs and BOR/DIR LANs at a dose of 5 mg/kg. Then,
the mice were scanned at 1, 2, 4, 8, 12 and 24 h using an Fx
Pro multimodal imaging system (Bruker Corp., USA).
In order to further observe the distribution in tumor masses
and the major organs, the tumor-bearing mice were sacrificed
at 24 h after heart perfusion with saline and 4% paraformal-
dehyde, followed by immediate removal of the brain, heart, liver,
spleen, lung, kidney and tumor masses.The fluorescence signal
intensities in different tissues were photographed.
2.8. Statistical analysis
Analysis of statistical significance was performed with the SPSS
statistics software16.0.The data are presented as the mean ± SD.
Student’s t-test was used to analyze the differences. The dif-
ferences were considered significant at P < 0.05.
3. Results and discussion
3.1. Characterization of BOR/PTX LANs
Particle size is a key factor determining the distribution of nano-
drug delivery system. It not only affects the nanoparticles
entering into tumor cells but also affects the drug accumula-
tion in tumor site. The particle size was determined by DLS
analysis (Fig. 1). The average size of the PTX LANs and BOR/
PTX LANs were 113.2 ± 4.5 nm, 107.5 ± 3.2 nm, respectively.
Therefore, most of the the PTX LANs or BOR/PTX LANs have
the potential to accumulate in tumor tissue by EPR effect [26].
Both PTX LANs and BOR/PTX LANs have high entrapment ef-
ficiency of 92.5 ± 1.8%, 90.4 ± 1.2%, respectively.The morphology
of the LANs was also shown in Fig. 1, they were spherical in
shape, an aqueous core surrounded by a multilayer structure
(lipid bilayers separated by a BSA-water interlayer). The BOR/
PTX-BSA conjugate located in the interlayer of the LANs. Both
BOR and PTX are hydrophobic and bind to albumin with high
affinity [27,28], and thus BOR/PTX can tightly bound to BSA to
form a BOR/PTX-BSA conjugate via hydrophobic interactions.
Then, the interactions between the BOR/PTX-BSA conjugate and
phosphatidylcholine molecule contribute to the formation of
the BOR/PTX LANs.
3.2. Cellular uptake
3.2.1. Cellular accumulation of PTX
In order to investigate the potential effect of BOR on P-gp me-
diated efflux, the cellular uptake of PTX was studied in C6
glioma cells in comparison with that of CsA, a typical P-gp in-
hibitor. As shown in Fig. 2, compared with Taxol, the cellular
uptake of Taxol (50 μg/ml PTX) with CsA (20 μg/ml) increased
markedly than that of Taxol without CsA. It is suggested that
BOR have an effect on inhibiting P-gp efflux pumps. In addi-
tion, the accumulation of PTX increased gradually with
increasing concentrations of BOR (0.001–1.0 μg/ml), and then
reached a plateau over a wide range of concentrations of BOR
(1.0–10.0 μg/ml). The result suggested that the effect of BOR on
inhibiting P-gp efflux pumps exhibits concentration depen-
dence and saturation properties. Furthermore, the cellular
uptake of PTX was greater than or equal to the standard P-gp
inhibitor CsA over a wide range of concentrations of BOR (1.0–
10.0 μg/ml). Moreover, the time dependence of PTX
accumulation was evaluated over 2 h with or without BOR
(Fig. 3). Taxol with BOR (1.0 μg/ml) shown an obvious increase
in PTX accumulation compared to Taxol alone at the time point
of 1 h and 2 h.
Fig. 1 – Size distribution and TEM image of PTX LANs, BOR/PTX LANs. (scale bar 200 nm in TEM image).
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The cellular uptake of LANs was also evaluated in C6 cells
after 2 h incubation (Fig. 4). BOR/PTX LANs showed more uptake
in comparison with the other formulations. The celluar uptake
of BOR/PTX LANs and PTX LANs showed 4.96-fold and 2.20-
fold increase compared with Taxol, respectivly. To confirm the
p-gp inhibition by BOR/PTX LANs, additional free CsA and BOR
was added in the incubation of C6 cells. The additional free
CsA and BOR along with PTX LANs significantly enhanced PTX
uptake to 2.89-fold and 3.46-fold, respectively. However, the ad-
dition of free CsA or BOR along with BOR/PTX LANs hardly
increased the PTX uptake. This indicated that BOR/PTX LANs
had sufficient ability to inhibit P-gp efflux of PTX without ad-
ditional CsA or BOR.
3.2.2. Confocal scanning microscopy
The confocal scanning microscopy was employed to visual-
ize the internalization and distribution of the LANs in C6
cells (Fig. 5). Both RDM LANs and BOR/RDM LANs showed
higher intensity of fluorescence than RDM solution at differ-
ent concentration (or different time). The results demonstrated
that the LANs could significantly increase the cellular uptake.
It could also be observed that the BOR/RDM LANs had the
strongest intensity of fluorescence at different concentration
(or different time). This can be ascribed to the BOR, as a P-gp
inhibitor, which could reduce intracellular RDM (P-gp sub-
strates) efflux to improve the cellular uptake. Moreover, at
the same time, the cellular uptake of RDM LANs and BOR/
RDM LANs could be obviously improved with increasing
concentration, suggesting concentration-dependent proper-
ties in the uptake of LANs. Additionally, at the same
concentration, the cellular uptake of PTX LANs and BOR/PTX
LANs could also be significantly enhanced with elevating the
incubation time, implying time-dependent properties in the
cellular uptake of the LANs.
3.2.3. Uptake mechanism
In order to clarify the internalization mechanism of the LANs
by C6 cells, the effects of various endocytosis inhibitors on cel-
lular uptake were investigated quantitatively. Chlorpromazine,
colchicine, indomethacine, quercetin and ammonium chlo-
ride were used to block clathrin-associated, macropinocytosis-
associated, caveolin-associated, clathrin- and caveolin-
independent and lysosome-associated endocytosis pathway
respectively. Sodium azide and 4 °C were employed to evalu-
ate the effect of energy on the cellular uptake. As shown in
Fig. 6, the cellular uptake was hindered significantly in the pres-
ence of chlorpromazine, suggesting that clathrin was involved
in the internalization of LANs. Ammonium chloride, a
lysosomotropic agent that inhibited the acidification of
endosome/lysosome, which decreased significantly the uptake
of LANs.This result indicated the endosome/lysosome pathway
was involved. Both 4 °C and sodium amide exhibited stron-
gest inhibition of cellular uptake, showing energy-dependent
properties in the uptake of LANs. On the contrary, colchicine,
indomethacine and quercetin, had no impact on the uptake,
Fig. 2 – Effect of BOR on cellular uptake of PTX at 37 °C for
2 h. Taxol: 50 μg/ml. CsA: 20 μg/ml. The concentration
range of BOR was 0.001–10.0 μg/ml (n = 3).
Fig. 3 – The time-dependent cellular uptake of PTX. Taxol:
50 μg/ml. BOR: 1.0 μg/ml *P < 0.05, compared with Taxol.
(n = 3).
Fig. 4 – Effect of BOR on cellular uptake of PTX LANs and
BOR/PTX LANs at 37 °C for 2 h. Taxol, PTX LANs and BOR/
PTX LANs: 50 μg/ml. CsA: 20 μg/ml. BOR: 1.0 μg/ml *P < 0.05,
compared with Control. (n = 3).
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suggesting that the endocytosis of PTX-LANs and BOR/PTX LANs
was not via macropinocytosis, caveolin-associated, clathrin-
and caveolin-independent endocytosis. Accordingly, the cel-
lular uptake of PTX-LANs and BOR/PTX LANs by C6 cells was
mainly mediated by clathrin and endosome/lysosome-
associated pathway. Moreover, both PTX LANs and BOR/PTX
LANs had similar uptake mechanism. It was reported that the
transport pathway of nanoparticles in cells depends on struc-
ture and physicochemical characteristics of nanoparticles (size,
shape, charge, surface properties, etc.), as well as cell types [29].
The result might be related to the similarity in structure and
physicochemical characteristics between PTX LANs and BOR/
PTX LANs.
3.3. Cytotoxicity
In order to investigate whether the increased intracellular PTX
accumulation by BOR/PTX LANs could increase its cytotoxicitys
in tumor cells. The cytotoxicity of PTX from different formu-
lations was tested against C6 glioma cells, and cell viability was
determined by the MTT assay after 72 h incubation. The com-
parison of IC50 values of Taxol, PTX LANs and BOR/PTX LANs
was shown in Table 1. Taxol and PTX LANs showed higher IC50
values of 1.54 μg/ml, 1.66 μg/ml in comparision with that of
BOR/PTX LANs (0.96 μg/ml). The results indicated that the cy-
totoxicity of Taxol and PTX LANs was almost the same from
the IC50 values. The cytotoxity of Taxol was attributed par-
tially to the Cremophor EL [30,31], whereas, the cytotoxicity of
the PTX LANs was only attributed to PTX. In particular, the BOR/
PTX LANs showed the lowest IC50 values, suggesting that the
BOR/PTX LANs did increased cytotoxicity against C6 glioma cells.
Two major reasons can be account for enhanced cytotoxicity
of BOR/PTX LANs in C6 cells. First, an increased extent of drug
uptake by endocytosis of nanoparticles, which helps to par-
tially bypass P-gp; second, a decreased efflux rate of drug
through inhibition of P-gp function by BOR.
Fig. 5 – The confocal microscopy images showing cellular uptake of Rhodamine 6G (RDM) from different formulations: The
concentration-dependent uptake after 2 h incubation (a) and time-dependent uptake at the RDM concentration of 10 μg/ml
(b). Original magnification: 10 × 20.
Fig. 6 – Effects of inhibitors and temperature on cellular
uptake of PTX LANs and BOR/PTX LANs at equal PTX
concentration of 50 μg/ml after 2 h incubation with C6
glioma cells. *P < 0.05, compared with Control. (n = 3).
Table 1 – IC50 values of the different PTX loaded LANs
formulations compared to Taxol. (n = 3).
Formulations Taxol PTX LANs BOR/PTX LANs
IC50 (μg/mL) 1.54 ± 0.09 1.66 ± 0.12 0.96 ± 0.08*
*P < 0.05, compared with Taxol or PTX LANs.
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Paclitaxel is a well-known anticancer drug, which has been
used in the treatment of wide range of cancers but its entry
into cancer cell is restricted by P-gp [32,33]. It was reported that
co-encapsulation of P-gp inhibitor and anticancer drug in
nanoparticles was an effective method to overcome P-gp efflux
in cancer chemotherapy, which can significantly improve the
cellular uptake of anticancer drugs [34–36]. In our study, we
encapsulated BOR in LANs to inhibit the P-gp efflux of PTX.
In vitro uptake experiments demonstrated that co-encapsulation
of BOR and PTX in LANs significantly increased the drug uptake
in comparison with that of Taxol and PTX LANs. Thus, BOR/
PTX LANs have the ability to inhibit P-gp efflux pumps, resulting
in a reduction of drug efflux and increasing the intracellular
accumulation of PTX. On basis of above mentioned results, three
reasons contributed to the enhancement of cellular uptake.
Firstly, after BOR/PTX LANs enter into cells, the intracellular
released BOR from BOR/PTX LANs could inhibit P-gp efflux, and
further increase the cellular accumulation of PTX. Secondly,
endocytosis of BOR/PTX LANs was ATP-consuming process,
which could reduce the activity of P-gp. Finally, the composi-
tion of the LANs was similar to the cell membrane consisting
of lipids and proteins, which probably have higher affinity to
the cell membrane of tumor cells, and thus increasing the LANs
entry the tumor cells by endocytosis. In a word, the more drugs
were accumulated, the higher cytotoxicity against tumor cells
could be obtained.
3.4. In vivo image
To evaluate the targeting effect of BOR/PTX LANs, C6 xeno-
graft bearing mice were used for in vivo imaging analysis. DIR-
labeled LANs were given intravenously into C6 tumor bearing
mice through the tail vein, and the DIR solution was used as
negative control. As shown in Fig. 7a, the fluorescence signal
was viewed in the tumor-bearing mice as early as 1 h after in-
jection. The maximum fluorescence signal was observed at 2 h
post-injection with gradually decrease after 24 h post-injection.
The fluorescence signal of LANs in the brain was higher com-
pared with DIR solution after i.v. administration. BOR/DIR LANs
has the strongest fluorescence signal until 24 h post-injection.
These results suggested that LANs could passively distribute
and accumulate in C6 xenografts by EPR effect. Moreover, co-
encapsulation with BOR could inhibit the P-gp mediated efflux
and further increase the accumulation of DIR in tumor site.
In order to investigate the tissue distribution of the LANs,
the ex vivo fluorescent images of the tissues were captured after
Fig. 7 – In vivo and ex vivo imaging. Fluorescent imaging of glioma bearing mice after i.v. administration with DIR solution,
DIR LANs and BOR/DIR LANs at dose of 5 mg/kg (a); ex vivo imaging at 24 h (b).
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24 h. As shown in Fig. 7b, the distribution of LANs in liver was
lower than that of DIR solution, indicating that LANs could
reduce toxicity in liver. Importantly, the distribution of BOR/
DIR LANs in tumor masses was higher than that of DIR LANs,
suggesting that co-encapsulation with BOR in LANs could in-
crease the distribution in tumors tissue and reduce its in liver.
Therefore, the BOR/PTX LANs could be a potential nano-
drug delivery system to enhance the anti-glioma effect. Further
studies in tumor models are needed to determine the in vivo
efficacy of BOR/PTX LANs.
4. Conclusion
Lipid-albumin nanoassemblies co-loaded with BOR and PTX
were prepared and characterized. Compared with PTX LANs,
BOR/PTX LANs significantly enhanced cytotoxicity in C6 glioma
cells. The cellular uptake of LANs was energy-, time- and
concentration-dependent, and clathrin- and endosome/
lysosome-associated pathways were involved. Furthermore,
in vivo image indicated that co-encapsulation of BOR in LANs
could obviously increase the accumulation of drug in tumor
tissues in comparison with the LANs without BOR. Therefore,
BOR/PTX LANs might be a promising drug delivery system for
improving the efficacy of chemotherapy by the combination
of drug delivery and P-gp inhibition.
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